Detailed Narrative
Strong Financial Performance in Q4 and FY25
Acutaas Chemical delivered a robust performance in Q4 FY25, with revenue growing 37.1% YoY to INR308.5 crores. Gross profit increased by 62.3% YoY to INR146 crores, leading to a gross margin of 47.3%. EBITDA for the quarter nearly doubled YoY to INR85 crores, with the EBITDA margin expanding by 835 bps YoY to 27.5%. For the full year FY25, the company crossed the INR1,000 crore revenue milestone, achieving INR1,006.9 crores, a 40.3% YoY growth, and PAT of INR160.4 crores, almost double the previous year.
Rebranding to Acutaas Chemicals Limited
To reflect its enlarged vision and diversified specialty chemicals portfolio, Ami Organics Limited announced its strategic decision to rename the company to Acutaas Chemicals Limited. This rebranding aims to honor its commitment to serving various industries including pharmaceutical, semiconductor, battery chemicals, petroleum, agrochemicals, cosmetics, and preservatives, while emphasizing its dedication to sustainable practices and humanity.
CDMO Business Momentum and Pipeline
The CDMO business remains a key growth driver, with management targeting INR1,000 crores in revenue from this segment by FY28. The company reported a 50% YoY growth in its Pharma Intermediates business for FY25, reaching INR854 crores. Several molecules within the core generic intermediates portfolio are expected to benefit from patent expirations in 2025 and 2026, further bolstering growth momentum.
Electrolyte Additives Business Development
The electrolyte additives business is on track, with production scheduled to commence from the new brownfield plant at Jhagadia site in H2 FY26. The plant will have a capacity of 2,000 metric tons each for VC and FEC. Management expects this segment to scale up and reach optimum capacity utilization within three years, contributing significantly to future revenue streams. A total capex of INR170 crores is allocated for this project, with INR35 crores already incurred.
Semiconductor Segment Recovery and Expansion
Despite subdued demand for legacy semiconductors, the company is actively expanding its reach in new geographies like Taiwan, Korea, and Japan, with new customer onboarding. The existing Baba Fine Chem business is being revamped, and management expects revenue visibility to ramp up in the next 1-2 years. The semiconductor business is seen as a pivotal role in future growth, though it requires time for approvals.
Capital Expenditure and Debt-Free Funding
The company incurred INR195 crores in capex for FY25, primarily for the Ankleshwar site, solar projects, and electrolyte additive projects. For FY26, capex is projected to be around INR200 crores, including spillover for electrolyte additives (INR130 crores) and maintenance/pilot plant (INR70 crores). Acutaas Chemical remains debt-free, with INR249 crores in net cash and cash equivalents, and plans to fund all upcoming capex through QIP proceeds and internal accruals.
Continuous Flow Chemistry Advancements
Acutaas Chemical has made significant progress in continuous flow chemistry over the last four years, converting several chemistries like esterification, chlorination, and diazotization. Capacities have been scaled up from 10 metric tons to 100 metric tons, with photo chlorination capacity reaching 1,000 metric tons. Some of these chemistries are already commercially operated, while others are under installation, indicating ongoing innovation and efficiency improvements.